ReviewAdvances in therapy2026
Therapeutic Adherence in Cardiovascular Diseases: Insights from the Patient and Physician-A Narrative Review.
Review in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Role of telemedicine in cardiovascular care in low- and middle-income countries (LMICs).American heart journal plus : cardiology research and practice · 2026Review
- Barriers and Facilitators to the Use of Novel Injectable Lipid-Lowering Therapies in Patients with Dyslipidemia or Cardiovascular Disease: A Scoping Review.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic adherence is defined as the extent to which patients' medication-taking behaviour corresponds with agreed recommendations from a clinician. Adherence to cardiovascular therapies significantly improves outcomes and improves patient quality of life. However, adherence is often suboptimal in patients with cardiovascular disease. This narrative review aims to describe key barriers to adherence and identify practical actions that can be undertaken by all stakeholders to improve treatment adherence. Key barriers fall into categories related to the patient, medication, healthcare system, disease and society. These include, but are not limited to, logistical challenges faced by patients incorporating medication into their daily lives, fragmented care, the patient-physician relationship, the complexity of the regimen and medication costs. While macro-initiatives to remove health system and societal barriers are encouraged, there are many practical ways in which patients can also be supported to adhere to medication. These include improving communication techniques to build a trusting physician-patient relationship, engaging other healthcare professionals (e.g. nurses and pharmacists), referral to patient advocacy groups for reliable information and peer support, simplifying treatment regimens where safe and appropriate, the use of digital tools or devices (e.g. pill boxes and symptom trackers) that help patients to take their medication in the right dose and at the right time and consideration of the patient's budgetary constraints when prescribing. Prescribing formulations for once-daily administration and single-pill combinations can also help to simplify treatment regimens. No single solution will fit all patients, and initiatives to enhance adherence must also be tailored wherever possible to the individual patient's abilities, circumstances, values and beliefs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.